Ramucirumab/Paclitaxel as Switch Maintenance in Advanced HER2-Negative Gastric/Gastroesophageal Junction Cancer
In an Italian phase III study (ARMANI) reported in The Lancet Oncology, Randon et al found that switch maintenance with ramucirumab/paclitaxel was associated with significantly improved progression-free survival vs continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric/gastroesophageal junction cancer.
Evidence-Based Recommendations and Knowledge Gaps Regarding Cardio-Oncology
A recent report highlighted evidence-based recommendations for the prevention, detection, and management of cancer therapy–related cardiovascular toxicity and cardiovascular events in patients with cancer, as well as knowledge gaps. Select considerations are summarized herein.
MRD-Guided Chemotherapy Intensification After Induction in Fit Older Patients With AML
As reported in the Journal of Clinical Oncology by Russell et al, the NCRI AML18 trial has shown survival benefit with treatment intensification in fit older patients with measurable residual disease (MRD)-positive response after first induction for acute myeloid leukemia (AML).
Radiotherapy With Durvalumab or Cetuximab in Locoregionally Advanced Head and Neck Cancer With Contraindication for Cisplatin
As reported in The Lancet Oncology by Mell et al, the phase II/III NRG-HN004 trial of radiotherapy with durvalumab or cetuximab in patients with locoregionally advanced head and neck squamous cell carcinoma and contraindications for cisplatin was stopped for futility during phase II; the phase III portion of the trial was not performed.
Pharmacokinetic Comparison of Aumolertinib, Osimertinib, Gefitinib, and Their Major Metabolites in NSCLC
Researchers may have established an accurate ultraperformance liquid chromatography–tandem mass spectrometry method for comparing the pharmacokinetic properties of three EGFR tyrosine kinase inhibitors and their major metabolites in mouse models and patients with non–small cell lung cancer (NSCLC), according to a recent study published by Bailleul et al in the National Science Review. The findings could provide a pharmacokinetic basis for the clinical application of aumolertinib and the development of next-generation EGFR TKIs.
IDEA Awardees’ Reflections on the 2024 ASCO Annual Meeting
Ramy Sedhom and colleagues on Optimizing Cancer Care for Older Adults
Ilana Hellmann: Reflections on a Father’s Cancer Journey
Connor J. Kinslow and colleagues on Breast Implant–Related Cancers
Lorcan Ruane and colleagues on Cardiotoxicity: How Far Have We Come?
Sponsored Content
SPONSORED BY THE BREAST CANCER INDEX® TEST BIOTHERANOSTICS, INC. A HOLOGIC COMPANY
Extended Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer: Tools for Decision-Making
SPONSORED BY LILLY MEDICAL AFFAIRS
CDK 4/6 Inhibitors for the Treatment of HR-Positive, HER2-Negative High-Risk Early Breast Cancer
SPONSORED BY LILLY MEDICAL AFFAIRS
Navigating the Treatment Landscape for Double-Refractory CLL/SLLMore Top Stories
The Future of Cancer Care, Part 2
The soaring number of cancer survivors since the National Cancer Act of 1971 was enacted into law provides a snapshot of the profound progress made against cancer over the past half-century: 3 million survivors in the 1970s,1 compared to more than 18 million today, and that number is expected to...
FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer
On December 4, 2024, the U.S. Food and Drug Administration approved durvalumab (Imfinzi) for adults with limited-stage small cell lung cancer (SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Efficacy was evaluated in ADRIATIC...
AI and the Future of Lung Cancer Screening: Still Room for Improvement
David F. Yankelevitz, MD Ella Kazerooni, MD, MS “Artificial intelligence [AI] will be used in all aspects of [lung cancer] screening…, and it continues to get better,” commented topic overview speaker David F. Yankelevitz, MD, Professor of Radiology at the Icahn School of Medicine at...
IMF Welcomes Newly Elected Board of Directors Members
Kent Oliver Maria Whitman The International Myeloma Foundation (IMF) welcomes four of its newest members to the IMF Board of Directors: Director of Strategic Growth at Raanes & Oliver Capital Advisors, Kent Oliver; Managing Partner of Global Commercialization Strategy and Solutions at ...
Alkylating Agent–Based Treatment in Neuroendocrine Tumors According to MGMT Status
In a French phase II trial (MGMT-NET) reported in the Journal of Clinical Oncology, Walter et al found evidence of activity of alkylating agent–based therapy among patients who have neuroendocrine tumors (NETs) with MGMT-deficient (dMGMT) status. Study Details In the multicenter open-label trial,...
Study Highlights From MD Anderson Researchers
Here are some highlights of clinical trials presented at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting by researchers from The University of Texas MD Anderson Cancer Center. They include breakthroughs in cancer care, updates in clinical research, and efforts in cancer...
De-escalated Neoadjuvant Treatment Adding Nab-Paclitaxel or Docetaxel/Carboplatin to Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer
In a Chinese phase III trial (HELEN-006) reported in The Lancet Oncology, Chen et al found that the de-escalated neoadjuvant treatment with the addition of nab-paclitaxel to trastuzumab/pertuzumab produced a higher pathologic complete response rate (pCR) vs docetaxel/carboplatin plus...
